Oncoclinicas do Brasil
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, ch… Read more
Oncoclinicas do Brasil (ONCO3) - Total Liabilities
Latest total liabilities as of September 2025: R$7.02 Billion BRL
Based on the latest financial reports, Oncoclinicas do Brasil (ONCO3) has total liabilities worth R$7.02 Billion BRL as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oncoclinicas do Brasil - Total Liabilities Trend (2013–2024)
This chart illustrates how Oncoclinicas do Brasil's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oncoclinicas do Brasil Competitors by Total Liabilities
The table below lists competitors of Oncoclinicas do Brasil ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nosa Med AB
ST:NOSA
|
Sweden | Skr25.36 Million |
|
Advtech
JSE:ADH
|
South Africa | ZAC4.68 Billion |
|
Renova Energia S.A
SA:RNEW11
|
Brazil | R$1.73 Billion |
|
Amata VN PCL
BK:AMATAV
|
Thailand | ฿7.89 Billion |
|
Jing-Jan Retail Business Co., Ltd.
TWO:2942
|
Taiwan | NT$3.64 Billion |
|
Duta Intidaya Tbk PT
JK:DAYA
|
Indonesia | Rp939.10 Billion |
|
Kesoram Industries Limited
NSE:KESORAMIND
|
India | ₹3.09 Billion |
|
Econergy Renewable Energy Ltd
TA:ECNR
|
Israel | ILA666.39 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Oncoclinicas do Brasil's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.06 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncoclinicas do Brasil's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncoclinicas do Brasil (2013–2024)
The table below shows the annual total liabilities of Oncoclinicas do Brasil from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | R$7.82 Billion | +20.27% |
| 2023-12-31 | R$6.50 Billion | +16.37% |
| 2022-12-31 | R$5.59 Billion | +49.90% |
| 2021-12-31 | R$3.73 Billion | +37.43% |
| 2020-12-31 | R$2.71 Billion | +86.55% |
| 2019-12-31 | R$1.45 Billion | +65.56% |
| 2018-12-31 | R$878.19 Million | +58.52% |
| 2017-12-31 | R$553.99 Million | +47.92% |
| 2016-12-31 | R$374.51 Million | +14.68% |
| 2015-12-31 | R$326.58 Million | -3.43% |
| 2014-12-31 | R$338.17 Million | +24.20% |
| 2013-12-31 | R$272.27 Million | -- |